IRTC vs the Top Picks average
| Pillar | IRTC | Book avg | Diff |
|---|---|---|---|
| Quality | 22 | 83 | -61 |
| Growth | 92 | 89 | +3 |
| Value | 15 | 76 | -61 |
Average of today's Top 30 (mean score 82.6); size and sector limits also decide the book.
One point per daily run; read From → To for the actual range.
IRTC at a glance
Same audited fundamentals as the score, unless a card says otherwise.
Analyst estimate revisions
| 30-day change | +5.6% |
|---|---|
| 90-day change | +21.9% |
| Forward EPS estimate | $1.28 |
Over the last 90 days, what analysts expect IRTC to earn is materially higher (+21.9%). The estimate is derived from price and forward P/E captured at the same instant, so a moving share price does not move this number — only a changed forecast does.
Estimates move both ways and are not part of the Bull Rankings score. Biggest movers →
Math only: excludes commissions, slippage and gap risk. Inputs stay in your browser.
iRhythm Holdings, Inc. (IRTC): score, valuation & FAQ
iRhythm Holdings, Inc. (IRTC) is a Medical Devices company that scores 31.3 out of 100 on the Bull Rankings quality-growth model — a weak reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are Rev (A-), while FCF (C-) and D/E (D) rate weaker. On valuation, IRTC sits about 432% above our discounted-cash-flow fair value — the current price implies free cash flow growing over 60% next year, slowing to 4% a year by year ten.
Is IRTC a good stock to buy?
Bull Rankings scores IRTC 31.3 out of 100 on its quality-growth model, which is a weak reading. That is driven by Rev (A-). A score is a quantitative screen of iRhythm Holdings, Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does IRTC score 31.3 on Bull Rankings?
The score leans on growth at 91.8 out of 100, with value the weakest pillar at 15.5 — the three combine geometrically, so a weak one cannot be papered over by a strong one. IRTC earns its highest marks on Rev (A-), and is held back by FCF (C-) and D/E (D). Each signal is graded against sector-aware thresholds rather than one absolute bar, so IRTC is measured against Medical Devices peers, not against the market as a whole.
Is IRTC overvalued or undervalued?
Based on $106.70, IRTC sits about 432% above our discounted-cash-flow fair value — the current price implies free cash flow growing over 60% next year, slowing to 4% a year by year ten. Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in IRTC?
D/E 3.91 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Currently unprofitable (margin -1.7%) — path to GAAP profitability is the core thesis risk. Down 50% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
New to these metrics? See the guides and the methodology.